This study will test an experimental drug called MGAWN1 for the treatment of West Nile infections.
Full Title of Study: “Expanded Access to MGAWN1 in Subjects With: Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection and a Compromised Immune System; or Substantial Accidental Exposure to West Nile Virus”
- Study Type: Expanded Access
The objective of this study is to provide expanded access to MGAWN1; the study is not intended for subjects who are eligible for and have access to non-expanded access protocols.
- Biological: MGAWN1
- Humanized monoclonal to West Nile virus. Dose=30mg/kg
Participating in This Clinical Trial
1. For West Nile Neuroinvasive Disease subjects: Have neurological signs and/or symptoms of West Nile meningitis, encephalitis, and/or acute flaccid paralysis 2. For immunocompromised subjects with suspected West Nile virus infection:
Gender Eligibility: All
Minimum Age: 8 Years
Maximum Age: N/A
- Lead Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Provider of Information About this Clinical Study
- Stanley Pillemer, M.D., Vice President of Clinical Research, MacroGenics, Inc
- Overall Official(s)
- Anastasia Daifotis, M.D., Study Director, MacroGenics
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.